1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

With Positive Data From Ionis, Angelman Syndrome Race Intensifies

 
• By Jessica Merrill

Ionis plans to initiate a Phase III trial for ION582 in the first half of 2025, positioning it just behind Ultragenyx in the race to bring a treatment to market for the rare neurologic condition.

Progress is being made in the treatment of Angelman syndrome • Source: Shutterstock

Ionis Pharmaceuticals, Inc. is looking to initiate a Phase III trial for ION582 as quickly as possible based on positive data announced on 22 July from the Phase I/II open-label HALOS study in people with the rare neurological condition Angelman syndrome (AS).

“Our top priority is to gain alignment with the FDA rapidly and to move ION582 into Phase III development as early as possible next year,” CEO Brett Monia said during...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.